Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19985698 | 1.00 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL25626705 | 1.00 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL30646926 | 0.88 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL15033787 | 0.87 | NR1H2 (0.56) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL17331292 | 0.87 | NR1H2 (0.56) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL10152546 | 0.86 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL28576704 | 0.86 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL21369480 | 0.86 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL22943927 | 0.84 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL25339238 | 0.84 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | NR1H2 2700/4885CHRM2 4883/4885CHRM1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.